Bioceltix

Bioceltix Working Capital Turnover

Working Capital Turnover of Bioceltix (BCX.WA) as of Oct 21, 2026.

Working Capital Turnover

0.00

Last updated:

Working Capital Turnover of Bioceltix is 2025 0.00 . Working Capital Turnover of Bioceltix was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioceltix Stock analysis

What does Bioceltix do? Bioceltix SA focuses on research and development within the field of veterinary medicine, specifically targeting the treatment of companion animals. The company develops candidates for veterinary medicinal products by utilizing the immunomodulatory properties of mesenchymal stem cells as the active substance. This scientific approach allows the firm to conduct research and development works that facilitate clinical trials and the full registration of these medicinal products with the European Medicines Agency, adhering to standards similar to those for human medicines. Bioceltix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioceltix stock

On Eulerpool you can find the complete historical development of Working Capital Turnover Bioceltix since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Bioceltix with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioceltix

All Key Metrics — Bioceltix